MedTrace Logo

Tirzepatide for Treatment of CCCA

NCT07734870 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-08-12

No results posted yet for this study

Summary

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are:

* Does tirzepatide improve the symptoms and signs of active CCCA?
* Does tirzepatide change the activity of genes in the scalp, especially genes related to scarring?
* Does tirzepatide promote hair regrowth?

Participants will:

* Inject tirzepatide once a week for 12 months.
* Visit the clinic for scalp examinations, photographs, and other health assessments.
* Have scalp biopsies at the beginning of the study and after 6 months of treatment.
* Have blood tests and other safety monitoring during the study.

There is no separate comparison group. Researchers will compare each participant's results during treatment with the participant's results at the beginning of the study.

Conditions

  • Central Centrifugal Cicatricial Alopecia (CCCA)

Interventions

DRUG

Tirzepatide

Tirzepatide solution will be self-administered by subcutaneous injection once weekly. Participants will receive 2.5 mg once weekly for the first 4 weeks, followed by 5 mg once weekly for the remainder of the 12-month treatment period. Injection sites will be rotated among the abdomen, thigh, or upper arm.

Sponsors & Collaborators

Principal Investigators

  • Crystal U Aguh, M.D. · The Johns Hopkins Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2028-05-25
Completion
2028-05-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07734870 on ClinicalTrials.gov